$-0.19 EPS Expected for Cumberland Pharmaceuticals Inc. (CPIX)

October 13, 2018 - By Peter Kolinski

Investors sentiment increased to 1.43 in Q2 2018. Its up 0.74, from 0.69 in 2018Q1. It increased, as 1 investors sold Cumberland Pharmaceuticals Inc. shares while 6 reduced holdings. 2 funds opened positions while 8 raised stakes. 4.12 million shares or 0.85% more from 4.09 million shares in 2018Q1 were reported.
Capital Advisers Lc holds 16,626 shares or 0% of its portfolio. Spark Investment Mngmt Limited Com accumulated 10,800 shares. State Street holds 13,490 shares or 0% of its portfolio. California Employees Retirement System reported 53,800 shares. Savings Bank Of New York Mellon has 20,338 shares. Cambridge Advsr reported 10,000 shares or 0% of all its holdings. Vanguard Incorporated has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Dimensional Fund L P reported 0% stake. The New York-based Ny State Common Retirement Fund has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Bard Associates Inc invested in 0.23% or 79,615 shares. Morgan Stanley reported 19,233 shares or 0% of all its holdings. Oakworth stated it has 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Delta Asset Management Limited Liability Tn holds 0.01% or 11,000 shares. Sei Invs reported 3,808 shares. Blackrock Inc has 0% invested in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 330,318 shares.

Since May 17, 2018, it had 2 buys, and 0 insider sales for $4,848 activity.

Analysts expect Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report $-0.19 EPS on November, 6.They anticipate $0.18 EPS change or 1,800.00 % from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, Cumberland Pharmaceuticals Inc.’s analysts see 1,800.00 % EPS growth. The stock increased 2.17% or $0.12 during the last trading session, reaching $5.66. About 1,510 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has declined 18.96% since October 13, 2017 and is downtrending. It has underperformed by 34.58% the S&P500.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Ratings Coverage

Among 2 analysts covering Cumberland (NASDAQ:CPIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cumberland had 3 analyst reports since April 17, 2018 according to SRatingsIntel. On Tuesday, April 17 the stock rating was initiated by FBR Capital with “Buy”. The stock of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has “Buy” rating given on Friday, August 17 by FBR Capital.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $88.12 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>